President, Ensisheim Partners, LLC
Director, MDRNA, Inc.

Dr. Quay joined the Company in August 2000 as Chairman, President and Chief Executive Officer. He served as President from August 2000 until December 2007, and as CEO until June 2008. In June 2008, Dr. Quay was appointed Chief Scientific Officer and Chairman of the Scientific Advisory Board. He remains Chairman of the Board of Directors. Dr. Quay founded and was Chairman, President and CEO of Atossa Healthcare, Inc., which focused on the development of a proprietary platform of diagnostics and treatments related to breast cancer risk assessment and therapeutics and other healthcare products for women. In 1991, Dr. Quay founded Sonus Pharmaceuticals, Inc., a company engaged in the research and development of drug delivery systems and oxygen delivery products based on emulsion and surfactant technology, where he served as CEO, President and a director until June 1999. In 1984, Dr. Quay founded Salutar, Inc. to develop contrast agents for magnetic resonance imaging. Two pharmaceuticals, OmniScan® and TeslaScan®, were invented by Dr. Quay at Salutar and are now FDA-approved for sale in the United States and other countries. Dr. Quay has authored more than 100 papers in diagnostic imaging, oncology, RNA interference and biochemistry and holds 65 U.S. patents. Dr. Quay graduated from the University of Michigan Medical School where he received an M.A. and a Ph.D. in biological chemistry in 1974 and 1975, respectively. He earned M.D. in 1977. Dr. Quay completed his post-graduate work in the chemistry department of Massachusetts Institute of Technology. Dr. Quay received his residency training at Massachusetts General Hospital, Harvard Medical School in Boston. From 1980 to 1986, he was a faculty member of Stanford University School of Medicine.

Partner, MSD Capital, LP

Eric Rosen is a partner of MSD Capital, LP, the private investment firm established to exclusively manage the capital of Michael S. Dell and his family. Mr. Rosen joined MSD Capital in 2005 and is responsible for leading the firm’s private equity investment activities. The firm currently manages over $10 billion of assets utilizing a multi-disciplinary approach to investing, encompassing traditional private equity, real estate and publicly-traded securities.

Previously, Mr. Rosen was a Managing Director of Onex Corporation, a diversified holding company and investment firm, and prior to joining Onex in 1989, he was a member of the Mergers & Acquisitions and Merchant Banking Groups of Kidder, Peabody & Co.

Mr. Rosen is currently on the Boards of OneWest Bank, a full service, California-based, thrift institution chartered by the OTS, ValleyCrest Companies, the largest North American commercial landscape installation and maintenance company, and DentalOne Partners, a dental practice management company. Additionally, Mr. Rosen is on the Board of New Alternatives for Children, a New York City-based not-for-profit agency serving children with medical disabilities and/or chronic illnesses and their families, is a member of the Board of Trustees of the Jewish Theological Seminary, and is a Trustee of the Stanford Graduate School of Business Trust.

Mr. Rosen received an MBA from the Stanford Graduate School of Business and a BS in Economics, magna cum laude, from the Wharton School of the University of Pennsylvania.

Donna Marie Seyfried

Independent Consultant

Donna Marie Seyfried is currently an independent consultant in business development and strategic planning focused on advanced molecular diagnostics and personalized medicine. With over 25 years of corporate experience in the development of emerging markets in biotechnology and healthcare, she has been instrumental in directing strategic investments, market development, and mergers and acquisitions in building high growth, profitable businesses in life sciences, molecular diagnostics and women’s health.

Prior to 2008, Ms. Seyfried served as Vice President, Business Development and Intellectual Property, and was an Officer of Digene Corporation from 1996 to 2007, until the company’s merger with Qiagen in 2007. Digene is a recognized molecular diagnostics leader in gene-based testing for the screening, diagnosis and monitoring of cancers and infectious diseases, focusing on women’s health. Ms. Seyfried was a key member of the Corporate Executive team which built the company and established HPV testing as the new standard of care for cervical cancer screening in women over 30 years old. During 1996-2007 HPV testing revenues grew from less than $5M to over $200M. Digene revolutionized cervical cancer screening with its’ proprietary HPV Test, the only FDA approved test for the human papilloma virus (HPV), the cause of cervical cancer.

Prior to joining Digene in 1996, Ms. Seyfried served as Director of Business Development for Applera (previously The Perkin-Elmer Corporation or "PE"). Ms. Seyfried was instrumental in PE’s strategic acquisitions of Applied Biosystems and Tropix, and directed PE’s strategic investments in several early stage molecular and chip-based companies. From 1987-1993, she served as the PCR Systems Business Manager during its most dynamic growth phase from less than $1m to $100m in revenues. Ms. Seyfried also worked for the Biomedical Products Division of Cambridge Instruments and E.I. Dupont de Nemours & Co.’s Clinical Diagnostics businesses.

Ms. Seyfried received her BS in Biology in 1980 from Lehigh University.

Daniel M. Skovronsky, MD, PhD

Founder and CEO
Avid Radiopharmaceuticals, Inc.

Dr. Skovronsky founded Avid Radiopharmaceuticals in 2005 and currently serves as its CEO. Avid Radiopharmaceuticals is a clinical-stage, product-focused molecular imaging company that has developed proprietary targeting agents to image amyloid plaques, and is currently testing these compounds in clinical trials for the detection of Alzheimer's disease. Prior to establishing Avid Radiopharmaceuticals, Dr. Skovronsky served as Scientific Director of High Throughput Screening and Drug Discovery at the Center for Neurodegenerative Disease Research at Penn from 2004-2005. He also trained at Penn, completing a Pathology residency and a Neuropathology fellowship at the Hospital of the University of Pennsylvania (2001-2005) and receiving an M.D., Ph.D. in Neuroscience from the School of Medicine (1994-2001).

Dr. Skovronsky has more than 20 peer-reviewed publications and has served as principal investigator or co-principal investigator on seven NIH funded grants since 2005. He and Avid Radiopharmaceuticals have received numerous scientific and business awards, such as the Frost & Sullivan Molecular Imaging Technology Innovation of the Year Award in 2007 and the American Society for Investigative Pathology’s Experimental Pathologist-in-Training Award in 2001. Additionally, Philadelphia Business Journal named him as one of their “Forty under Forty” business leaders in the region in 2006, and PharmaVoice Magazine named him among the “Top 100 Pharmaceutical Business Leaders” in 2007.